Question 1
Which of the following best describes the mechanism of action of erythropoiesis-stimulating agents (ESAs)?
A) Inhibition of red blood cell destruction
B) Stimulation of erythropoietin receptors on erythroid progenitor cells
C) Suppression of the immune response to prevent anemia
D) Inhibition of hemoglobin synthesis
E) Blocking iron absorption in the gastrointestinal tract
Click here to see the answer
Correct Answer: B) Stimulation of erythropoietin receptors on erythroid progenitor cells
Explanation: ESAs work by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, stimulating the production and differentiation of red blood cells.
Question 2
Which of the following is an indication for the use of erythropoiesis-stimulating agents (ESAs)?
A) Iron-deficiency anemia
B) Anemia in chronic kidney disease (CKD)
C) Pernicious anemia
D) Anemia due to acute blood loss
E) Hemolytic anemia
Click here to see the answer
Correct Answer: B) Anemia in chronic kidney disease (CKD)
Explanation: ESAs are commonly used to treat anemia associated with chronic kidney disease, particularly in patients on dialysis or with advanced kidney disease.
Question 3
Which of the following is a common side effect of erythropoiesis-stimulating agents (ESAs) that requires careful monitoring?
A) Hypotension
B) Thrombocytopenia
C) Hypertension
D) Hyperglycemia
E) Neutropenia
Click here to see the answer
Correct Answer: C) Hypertension
Explanation: ESAs can increase blood pressure, particularly in patients with CKD, so careful monitoring for hypertension is necessary.
Question 4
Which of the following adverse outcomes is associated with targeting hemoglobin levels above 11.5 g/dL in patients receiving erythropoiesis-stimulating agents (ESAs)?
A) Increased risk of infection
B) Increased risk of thromboembolic events and stroke
C) Increased risk of gastrointestinal bleeding
D) Increased risk of osteoporosis
E) Increased risk of leukopenia
Click here to see the answer
Correct Answer: B) Increased risk of thromboembolic events and stroke
Explanation: Targeting hemoglobin levels above 11.5 g/dL with ESAs is associated with an increased risk of thromboembolic events, stroke, and cardiovascular complications.
Question 5
Which of the following patient populations should be monitored closely when receiving erythropoiesis-stimulating agents due to the risk of shortened survival and tumor progression?
A) Chronic kidney disease patients
B) Pediatric patients
C) Cancer patients
D) Patients with iron-deficiency anemia
E) Post-surgical patients
Click here to see the answer
Correct Answer: C) Cancer patients
Explanation: In cancer patients, ESAs can shorten overall survival and increase the risk of tumor progression or recurrence, requiring close monitoring.
Question 6
Which of the following laboratory values should be regularly monitored in patients receiving erythropoiesis-stimulating agents to ensure effective erythropoiesis?
A) Serum calcium levels
B) Hemoglobin levels and iron status (ferritin and transferrin saturation)
C) Serum glucose levels
D) Platelet counts
E) Liver function tests
Click here to see the answer
Correct Answer: B) Hemoglobin levels and iron status (ferritin and transferrin saturation)
Explanation: Hemoglobin levels and iron status should be monitored regularly in patients receiving ESAs to ensure that erythropoiesis is effective and that iron stores are adequate.
Question 7
Which of the following best describes the primary mechanism of action of phosphate binders in managing hyperphosphatemia?
A) Increasing renal excretion of phosphate
B) Binding dietary phosphate in the gastrointestinal tract, preventing its absorption
C) Stimulating the release of parathyroid hormone (PTH)
D) Enhancing the secretion of calcium in the kidneys
E) Inhibiting the synthesis of phosphate in the liver
Click here to see the answer
Correct Answer: B) Binding dietary phosphate in the gastrointestinal tract, preventing its absorption
Explanation: Phosphate binders work by binding dietary phosphate in the gastrointestinal tract, preventing its absorption and helping to lower serum phosphate levels in patients with CKD.
Question 8
Which of the following phosphate binders is non-calcium-based and may also have the added benefit of lowering LDL cholesterol levels?
A) Calcium carbonate
B) Calcium acetate
C) Sevelamer
D) Magnesium hydroxide
E) Aluminum hydroxide
Click here to see the answer
Correct Answer: C) Sevelamer
Explanation: Sevelamer is a non-calcium, non-metal-based phosphate binder that can also lower LDL cholesterol levels, providing cardiovascular benefits.
Question 9
Which of the following is a common side effect of calcium acetate, a calcium-based phosphate binder?
A) Metabolic acidosis
B) Hypercalcemia
C) Hypocalcemia
D) Hyponatremia
E) Hyperkalemia
Click here to see the answer
Correct Answer: B) Hypercalcemia
Explanation: Calcium acetate can cause hypercalcemia, which increases the risk of vascular calcification, cardiac complications, and bone pain in patients with CKD.
Question 10
Which phosphate binder is more likely to cause mild metabolic acidosis, particularly in patients with chronic kidney disease?
A) Sevelamer carbonate
B) Sevelamer hydrochloride
C) Calcium acetate
D) Magnesium carbonate
E) Calcium carbonate
Click here to see the answer
Correct Answer: B) Sevelamer hydrochloride
Explanation: Sevelamer hydrochloride has been associated with mild metabolic acidosis, while sevelamer carbonate has a reduced risk of this side effect.
Question 11
Which of the following is an indication for the use of phosphate binders such as sevelamer and calcium acetate?
A) Hyperphosphatemia in chronic kidney disease
B) Hypocalcemia in hypoparathyroidism
C) Hypercalcemia in hyperparathyroidism
D) Osteoporosis in postmenopausal women
E) Hyperkalemia in chronic kidney disease
Click here to see the answer
Correct Answer: A) Hyperphosphatemia in chronic kidney disease
Explanation: Phosphate binders are indicated for the management of hyperphosphatemia in patients with chronic kidney disease who have difficulty excreting phosphate.
Question 12
Which of the following is an advantage of using sevelamer over calcium acetate in managing hyperphosphatemia?
A) Sevelamer provides additional calcium
B) Sevelamer reduces the risk of hypercalcemia
C) Sevelamer is more effective in lowering phosphate levels
D) Sevelamer is absorbed better in the kidneys
E) Sevelamer increases renal excretion of phosphate
Click here to see the answer
Correct Answer: B) Sevelamer reduces the risk of hypercalcemia
Explanation: Sevelamer is a non-calcium-based phosphate binder, reducing the risk of hypercalcemia, making it useful for patients at risk of elevated calcium levels.
Question 13
What is the primary mechanism of action of sodium bicarbonate in the treatment of metabolic acidosis?
A) Enhances renal excretion of potassium
B) Blocks the production of hydrochloric acid
C) Neutralizes excess hydrogen ions (H⁺) in the blood
D) Inhibits the secretion of gastric acid
E) Increases bicarbonate production in the liver
Click here to see the answer
Correct Answer: C) Neutralizes excess hydrogen ions (H⁺) in the blood
Explanation: Sodium bicarbonate dissociates into bicarbonate ions (HCO₃⁻), which neutralize excess hydrogen ions (H⁺) in the blood, helping to correct metabolic acidosis by increasing blood pH.
Question 14
In which of the following conditions is sodium bicarbonate commonly used as part of the treatment to alkalinize the urine and increase toxin excretion?
A) Hypercalcemia
B) Hypokalemia
C) Salicylate toxicity (aspirin overdose)
D) Rhabdomyolysis
E) Hypoglycemia
Click here to see the answer
Correct Answer: C) Salicylate toxicity (aspirin overdose)
Explanation: Sodium bicarbonate is used in salicylate toxicity to alkalinize the urine, which enhances the excretion of the toxin by increasing the ionization of salicylates and preventing their reabsorption in the kidneys.
Question 15
Which of the following is a common side effect of oral sodium bicarbonate therapy?
A) Hypoglycemia
B) Fluid retention and hypertension
C) Hypercalcemia
D) Bradycardia
E) Myopathy
Click here to see the answer
Correct Answer: B) Fluid retention and hypertension
Explanation: Sodium bicarbonate contains sodium, which can lead to fluid retention, hypertension, and exacerbation of heart failure, particularly in patients with pre-existing cardiovascular conditions.
Question 16
Which of the following conditions can result from the overuse of sodium bicarbonate?
A) Metabolic alkalosis
B) Metabolic acidosis
C) Hyperkalemia
D) Respiratory alkalosis
E) Hypernatremia
Click here to see the answer
Correct Answer: A) Metabolic alkalosis
Explanation: Overuse of sodium bicarbonate can lead to metabolic alkalosis, a condition characterized by elevated blood pH, which can cause symptoms like muscle twitching, nausea, vomiting, and confusion.
Question 17
Which of the following clinical scenarios involves the use of sodium bicarbonate to temporarily shift potassium back into cells?
A) Hypokalemia
B) Hyperkalemia
C) Hypercalcemia
D) Hypoglycemia
E) Hyponatremia
Click here to see the answer
Correct Answer: B) Hyperkalemia
Explanation: In cases of life-threatening hyperkalemia, sodium bicarbonate can be used to alkalinize the blood, which helps shift potassium back into cells temporarily, thereby reducing serum potassium levels.
Question 18
Which of the following best describes the primary mechanism of action of calcitriol?
A) Inhibition of calcium excretion by the kidneys
B) Enhancement of calcium absorption from the intestines and reduction of calcium excretion by the kidneys
C) Stimulation of bone formation by osteoblasts
D) Reduction of parathyroid hormone (PTH) secretion by increasing phosphate excretion
E) Inhibition of vitamin D receptor (VDR) activation in the kidneys
Click here to see the answer
Correct Answer: B) Enhancement of calcium absorption from the intestines and reduction of calcium excretion by the kidneys
Explanation: Calcitriol increases calcium absorption from the intestines, reduces calcium excretion by the kidneys, and promotes calcium release from bones by binding to the vitamin D receptor (VDR) in target tissues.
Question 19
Which of the following conditions is not an appropriate indication for calcitriol therapy?
A) Hypoparathyroidism
B) Hypocalcemia in chronic kidney disease
C) Vitamin D-resistant rickets
D) Hypercalcemia
E) Osteomalacia
Click here to see the answer
Correct Answer: D) Hypercalcemia
Explanation: Calcitriol is contraindicated in patients with hypercalcemia, as it can further increase serum calcium levels and lead to adverse effects such as kidney stones and confusion.
Question 20
Which of the following is a common side effect of calcitriol therapy?
A) Hypercalcemia
B) Hypophosphatemia
C) Hypokalemia
D) Hypocalciuria
E) Hypermagnesemia
Click here to see the answer
Correct Answer: A) Hypercalcemia
Explanation: Hypercalcemia is the most common side effect of calcitriol therapy, often leading to symptoms such as nausea, vomiting, fatigue, and confusion.
Question 21
Which of the following medications increases the risk of hypercalcemia when used in combination with calcitriol?
A) Phenytoin
B) Barbiturates
C) Thiazide diuretics
D) Magnesium-containing antacids
E) Furosemide
Click here to see the answer
Correct Answer: C) Thiazide diuretics
Explanation: Thiazide diuretics decrease calcium excretion by the kidneys, increasing the risk of hypercalcemia when used with calcitriol.
Question 22
Which of the following drugs may reduce calcitriol levels by increasing its metabolism?
A) Magnesium-containing antacids
B) Phenytoin
C) Calcium carbonate
D) Furosemide
E) Spironolactone
Click here to see the answer
Correct Answer: B) Phenytoin
Explanation: Phenytoin and barbiturates can reduce calcitriol levels by increasing its metabolism, potentially reducing its therapeutic effects.
Question 23
In which of the following conditions would calcitriol most likely be used to manage calcium and phosphate metabolism?
A) Hypokalemia
B) Chronic kidney disease (CKD)
C) Hypercalcemia
D) Iron-deficiency anemia
E) Gout
Click here to see the answer
Correct Answer: B) Chronic kidney disease (CKD)
Explanation: Calcitriol is used to manage calcium and phosphate metabolism in patients with chronic kidney disease (CKD) who have impaired renal function and are at risk of hypocalcemia.
Question 24
Which of the following best describes the primary mechanism of action of cinacalcet?
A) Enhances calcium absorption from the intestines
B) Increases sensitivity of calcium-sensing receptors on the parathyroid gland
C) Inhibits calcium reabsorption in the kidneys
D) Stimulates the release of parathyroid hormone (PTH)
E) Blocks vitamin D receptors in the kidneys
Click here to see the answer
Correct Answer: B) Increases sensitivity of calcium-sensing receptors on the parathyroid gland
Explanation: Cinacalcet increases the sensitivity of the calcium-sensing receptors on the parathyroid gland to extracellular calcium, resulting in decreased secretion of parathyroid hormone (PTH) and lower serum calcium and phosphate levels.
Question 25
For which of the following conditions is cinacalcet commonly indicated?
A) Hyperkalemia in chronic kidney disease
B) Osteoporosis
C) Secondary hyperparathyroidism in patients on dialysis
D) Hypercalcemia of malignancy
E) Hypoparathyroidism
Click here to see the answer
Correct Answer: C) Secondary hyperparathyroidism in patients on dialysis
Explanation: Cinacalcet is used to lower PTH levels in patients with secondary hyperparathyroidism due to chronic kidney disease (CKD) on dialysis.
Question 26
Which of the following is a common side effect of cinacalcet therapy?
A) Hypercalcemia
B) Hypocalcemia
C) Hyperkalemia
D) Hypophosphatemia
E) Hypertension
Click here to see the answer
Correct Answer: B) Hypocalcemia
Explanation: Cinacalcet can cause hypocalcemia due to its action on the calcium-sensing receptors, leading to reduced PTH secretion and lower serum calcium levels.
Question 27
Cinacalcet is contraindicated in which of the following conditions?
A) Hyperphosphatemia
B) Hypocalcemia
C) Hypercalcemia
D) Hyponatremia
E) Hypokalemia
Click here to see the answer
Correct Answer: B) Hypocalcemia
Explanation: Cinacalcet is contraindicated in patients with pre-existing hypocalcemia because it can further lower serum calcium levels, potentially causing serious complications.
Question 28
Which of the following serious side effects can occur with prolonged use of cinacalcet due to excessive suppression of parathyroid hormone (PTH)?
A) Hypercalcemia
B) Adynamic bone disease
C) Hyperphosphatemia
D) Osteoporosis
E) Hypophosphatemia
Click here to see the answer
Correct Answer: B) Adynamic bone disease
Explanation: Prolonged suppression of PTH with cinacalcet can lead to adynamic bone disease, a condition characterized by reduced bone turnover and weakened bone structure.
Question 29
Cinacalcet is known to interact with which of the following classes of drugs by inhibiting the metabolism of their substrates?
A) CYP3A4 inhibitors
B) CYP2D6 substrates
C) CYP2C9 inducers
D) MAO inhibitors
E) NSAIDs
Click here to see the answer
Correct Answer: B) CYP2D6 substrates
Explanation: Cinacalcet inhibits CYP2D6, which can affect the metabolism of drugs that are CYP2D6 substrates, such as metoprolol and certain tricyclic antidepressants.
Question 30
Why is metformin use often temporarily discontinued before the administration of radiocontrast media?
A) Risk of hypoglycemia
B) Risk of hypercalcemia
C) Risk of lactic acidosis due to potential nephrotoxicity
D) Risk of gastrointestinal upset
E) Risk of hyperkalemia
Click here to see the answer
Correct Answer: C) Risk of lactic acidosis due to potential nephrotoxicity
Explanation: Metformin is temporarily discontinued before the administration of radiocontrast media due to the risk of lactic acidosis, especially in patients with impaired renal function or potential nephrotoxicity caused by the contrast agent.
Question 31
Which of the following conditions increases the risk of nephrotoxicity after administration of radiocontrast media?
A) Hypercalcemia
B) Chronic kidney disease (CKD)
C) Hyperglycemia
D) Hyponatremia
E) Hypokalemia
Click here to see the answer
Correct Answer: B) Chronic kidney disease (CKD)
Explanation: Patients with chronic kidney disease (CKD) are at an increased risk of nephrotoxicity following radiocontrast media administration due to reduced renal clearance and potential further impairment of kidney function.
Question 32
Which of the following is a preventive measure to reduce the risk of nephrotoxicity in patients receiving radiocontrast media?
A) Increase potassium intake
B) Pre-hydration with IV fluids
C) Administer furosemide before the procedure
D) Reduce calcium intake
E) Administer metformin before the procedure
Click here to see the answer
Correct Answer: B) Pre-hydration with IV fluids
Explanation: Pre-hydration with intravenous fluids before and after the administration of radiocontrast media is an effective preventive measure to reduce the risk of contrast-induced nephrotoxicity.
Question 33
Which of the following is a possible complication of nephrotoxicity caused by radiocontrast media?
A) Hyperglycemia
B) Acute kidney injury (AKI)
C) Hypophosphatemia
D) Hypernatremia
E) Hypertension
Click here to see the answer
Correct Answer: B) Acute kidney injury (AKI)
Explanation: Nephrotoxicity from radiocontrast media can lead to acute kidney injury (AKI), characterized by a sudden decline in renal function and reduced glomerular filtration rate (GFR).
Question 34
Which of the following patients should be closely monitored when receiving radiocontrast media due to the risk of nephrotoxicity?
A) A patient with asthma
B) A patient with type 2 diabetes on metformin
C) A patient with hypothyroidism
D) A patient with hyperlipidemia
E) A patient with osteoporosis
Click here to see the answer
Correct Answer: B) A patient with type 2 diabetes on metformin
Explanation: Patients with type 2 diabetes on metformin should be closely monitored when receiving radiocontrast media due to the risk of lactic acidosis in the event of contrast-induced nephrotoxicity, which could impair metformin clearance.
Question 35
How long should metformin typically be held after the administration of radiocontrast media in patients at risk of nephrotoxicity?
A) 6 hours
B) 12 hours
C) 24 hours
D) 48 hours
E) 72 hours
Click here to see the answer
Correct Answer: D) 48 hours
Explanation: Metformin should typically be held for 48 hours after the administration of radiocontrast media in patients at risk of nephrotoxicity, pending assessment of renal function to ensure it has not been impaired.